-

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

original The poster presented by Inocras at ASCO Annual Meeting (Photo: Inocras)

The poster presented by Inocras at ASCO Annual Meeting (Photo: Inocras)

SAN DIEGO--(BUSINESS WIRE)--Inocras Inc., a leader in whole genome sequencing (WGS) diagnostics and precision medicine, is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer. Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.

HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment. Although BRCA1/2 germline mutations are rare (1%-5%), WGS has revealed that up to 22% of breast cancers display HRD-like genomic characteristics. The study utilized a WGS-HRD approach to identify and validate radiomic features with predictive value for HRD, highlighting their potential as non-invasive imaging biomarkers for primary HRD screening1.

“This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

Combining WGS-powered genomic data with radiomic insights may enhance the accuracy of HRD screening and optimize treatment strategies. This approach has the potential to benefit a wider range of breast cancer patients, extending beyond those with detectable BRCA1/2 germline mutations, and to advance personalized medicine in oncology.

1. Joonoh Lim et al, Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing. J Clin Oncol 42, 2024 (suppl 16; abstr e15044) 10.1200/JCO.2024.42.16_suppl.e15044

About Inocras Inc:

Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases. The company is dedicated to unlocking the potential of whole genomic data to enable precision health for everyone.

Contacts

Sohee Cho / media@inocras.com

Industry:

Inocras Inc.

Release Versions
English

Contacts

Sohee Cho / media@inocras.com

More News From Inocras Inc.

Inocras and Broad Institute Researchers Present New TCGA Whole-Genome Cancer Insights, Accelerating Discovery in Cancer Genomics

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer wh...

Inocras and Broad Institute Researchers Will Release Novel Insights From TCGA Cancer Whole-Genome Analysis at AACR Annual Meeting 2026, Empowering a New Era of Precision Oncology

SAN DIEGO--(BUSINESS WIRE)--Researchers at Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary analytics, and the Broad Institute jointly announced the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers. “NCI’s public The Cancer Genome Atlas (TCGA) ef...

Inocras and NDS Partner to Deliver Clinical-Scale Whole-Genome Cancer Analytics in the Cloud

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Inocras, a bioinformatics-led company harnessing the power of whole genome data and proprietary analytics to deliver curated insights, today announced a strategic partnership with NDS Corporation (NDS), a South Korean IT services provider specialized in healthcare data and cloud solutions. Together, the companies will jointly develop and commercialize cloud-based genomic analysis platforms for healthcare providers, in South Korea and key global m...
Back to Newsroom